Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Check out the new look and feel of Harvard Catalyst Profiles! Learn more on our About and Help pages.

David Allen Reardon, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. P50CA108786 (BIGNER, DARELL D) Jul 1, 2004 - Aug 31, 2010
    NIH/NCI
    SPORE in Brain Cancer
    Role: Co-Principal Investigator
  2. R21CA105781 (REARDON, DAVID A) Sep 29, 2003 - Aug 31, 2006
    NIH/NCI
    Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    Role: Principal Investigator
  3. P20CA096890 (BIGNER, DARELL D) Sep 30, 2002 - Aug 31, 2004
    NIH/NCI
    SPORE in Brain Cancer
    Role: Co-Principal Investigator
  4. P50NS020023 (BIGNER, DARELL D) Apr 1, 1984 - Jan 31, 2014
    NIH/NINDS
    SRC on Primary Tumors of the CNS
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2018 Jun 18; 20(7):897-906. PMID: 29788429.
    View in: PubMed
  2. Gan HK, Reardon DA, Lassman AB, Merrell R, van den Bent M, Butowski N, Lwin Z, Wheeler H, Fichtel L, Scott AM, Gomez EJ, Fischer J, Mandich H, Xiong H, Lee HJ, Munasinghe WP, Roberts-Rapp LA, Ansell PJ, Holen KD, Kumthekar P. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro Oncol. 2018 May 18; 20(6):838-847. PMID: 29077941.
    View in: PubMed
  3. Melosky B, Reardon DA, Nixon AB, Subramanian J, Bair AH, Jacobs I. Bevacizumab biosimilars: scientific justification for extrapolation of indications. Future Oncol. 2018 Apr 25. PMID: 29690784.
    View in: PubMed
  4. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018 Apr 09; 20(5):674-686. PMID: 29106665.
    View in: PubMed
  5. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Validation of post-operative residual contrast enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 Apr 05. PMID: 29660006.
    View in: PubMed
  6. Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 Apr 05. PMID: 29660005.
    View in: PubMed
  7. Platten M, Reardon DA. Concepts for Immunotherapies in Gliomas. Semin Neurol. 2018 Feb; 38(1):62-72. PMID: 29548053.
    View in: PubMed
  8. Nakashima H, Nguyen T, Kasai K, Passaro C, Ito H, Goins WF, Shaikh I, Erdelyi R, Nishihara R, Nakano I, Reardon DA, Anderson AC, Kuchroo V, Chiocca EA. Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clin Cancer Res. 2018 Jun 01; 24(11):2574-2584. PMID: 29511029.
    View in: PubMed
  9. Coy S, Rashid R, Lin JR, Du Z, Donson AM, Hankinson TC, Foreman NK, Manley PE, Kieran MW, Reardon DA, Sorger PK, Santagata S. Multiplexed Immunofluorescence Reveals Potential PD-1/PD-L1 Pathway Vulnerabilities in Craniopharyngioma. Neuro Oncol. 2018 Mar 02. PMID: 29509940.
    View in: PubMed
  10. Zhou M, Zhou Y, Liao H, Rowland BC, Kong X, Arvold ND, Reardon DA, Wen PY, Lin AP, Huang RY. Diagnostic Accuracy of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy in Newly-Diagnosed Brain Mass and Suspected Recurrent Gliomas. Neuro Oncol. 2018 Feb 09. PMID: 29438510.
    View in: PubMed
  11. Happold C, Gorlia T, Nabors LB, Erridge SC, Reardon DA, Hicking C, Picard M, Stupp R, Weller M. Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma? J Neurooncol. 2018 May; 138(1):163-171. PMID: 29423540.
    View in: PubMed
  12. Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 Jan 22; 20(2):249-258. PMID: 29016998.
    View in: PubMed
  13. Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 Jan 22; 20(2):259-267. PMID: 29036345.
    View in: PubMed
  14. Speranza MC, Passaro C, Ricklefs F, Kasai K, Klein SR, Nakashima H, Kaufmann JK, Ahmed AK, Nowicki MO, Obi P, Bronisz A, Aguilar-Cordova E, Aguilar LK, Guzik BW, Breakefield X, Weissleder R, Freeman GJ, Reardon DA, Wen PY, Chiocca EA, Lawler SE. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 2018 Jan 22; 20(2):225-235. PMID: 29016938.
    View in: PubMed
  15. Nakashima H, Alayo QA, Penaloza-MacMaster P, Freeman GJ, Kuchroo VK, Reardon DA, Fernandez S, Caligiuri M, Chiocca EA. Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep. 2018 Jan 09; 8(1):208. PMID: 29317703.
    View in: PubMed
  16. Peters KB, Lipp ES, Miller E, Herndon JE, McSherry F, Desjardins A, Reardon DA, Friedman HS. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. J Neurooncol. 2018 Apr; 137(2):349-356. PMID: 29264836.
    View in: PubMed
  17. Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 Apr 01; 124(7):1438-1448. PMID: 29266174.
    View in: PubMed
  18. Nayak L, Reardon DA. High-grade Gliomas. Continuum (Minneap Minn). 2017 Dec; 23(6, Neuro-oncology):1548-1563. PMID: 29200110.
    View in: PubMed
  19. Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts HJWL. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017 Nov 29; 19(12):1688-1697. PMID: 28499022.
    View in: PubMed
  20. Ghiaseddin A, Reardon D, Massey W, Mannerino A, Lipp ES, Herndon JE, McSherry F, Desjardins A, Randazzo D, Friedman HS, Peters KB. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. Oncologist. 2018 Feb; 23(2):157-e21. PMID: 29133513.
    View in: PubMed
  21. Reardon DA, Wucherpfennig K, Chiocca EA. Immunotherapy for glioblastoma: on the sidelines or in the game? Discov Med. 2017 11; 24(133):201-208. PMID: 29278673.
    View in: PubMed
  22. van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study. Cancer Chemother Pharmacol. 2017 Dec; 80(6):1209-1217. PMID: 29075855.
    View in: PubMed
  23. Arvold ND, Shi DD, Aizer AA, Norden AD, Reardon DA, Lee EQ, Nayak L, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Wen PY, Alexander BM. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017 Dec; 135(3):581-591. PMID: 28975467.
    View in: PubMed
  24. Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V, Perry JR, Hyun Nam D, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, Baumert BG, Mehta MP, van den Bent MJ, Reardon DA, Weller M, Stupp R. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol. 2017 Aug 01; 19(8):1119-1126. PMID: 28371907.
    View in: PubMed
  25. Gan HK, van den Bent M, Lassman AB, Reardon DA, Scott AM. Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells. Nat Rev Clin Oncol. 2017 Nov; 14(11):695-707. PMID: 28675164.
    View in: PubMed
  26. Reardon DA, Lassman AB, van den Bent M, Kumthekar P, Merrell R, Scott AM, Fichtel L, Sulman EP, Gomez E, Fischer J, Lee HJ, Munasinghe W, Xiong H, Mandich H, Roberts-Rapp L, Ansell P, Holen KD, Gan HK. Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):965-975. PMID: 28039367.
    View in: PubMed
  27. Reardon DA, Wen PY, Wucherpfennig KW, Sampson JH. Immunomodulation for glioblastoma. Curr Opin Neurol. 2017 06; 30(3):361-369. PMID: 28368867.
    View in: PubMed
  28. Weller M, Roth P, Preusser M, Wick W, Reardon DA, Platten M, Sampson JH. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol. 2017 Jun; 13(6):363-374. PMID: 28497804.
    View in: PubMed
  29. Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, Suijkerbuijk KPM, Azevedo S, Li H, Reshef D, Avila A, Reardon DA. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist. 2017 06; 22(6):709-718. PMID: 28495807.
    View in: PubMed
  30. Hundsberger T, Reardon DA, Wen PY. Angiogenesis inhibitors in tackling recurrent glioblastoma. Expert Rev Anticancer Ther. 2017 Jun; 17(6):507-515. PMID: 28438066.
    View in: PubMed
  31. Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017 05 01; 19(5):625-635. PMID: 28453751.
    View in: PubMed
  32. Shankar GM, Abedalthagafi M, Vaubel RA, Merrill PH, Nayyar N, Gill CM, Brewster R, Bi WL, Agarwalla PK, Thorner AR, Reardon DA, Al-Mefty O, Wen PY, Alexander BM, van Hummelen P, Batchelor TT, Ligon KL, Ligon AH, Meyerson M, Dunn IF, Beroukhim R, Louis DN, Perry A, Carter SL, Giannini C, Curry WT, Cahill DP, Barker FG, Brastianos PK, Santagata S. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545. PMID: 28170043.
    View in: PubMed
  33. Reardon DA, Mitchell DA. The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol. 2017 02; 39(2):225-239. PMID: 28138787.
    View in: PubMed
  34. Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol. 2017 Mar; 111:60-65. PMID: 28259296.
    View in: PubMed
  35. Qin L, Li X, Stroiney A, Qu J, Helgager J, Reardon DA, Young GS. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma. Neuroradiology. 2017 Feb; 59(2):135-145. PMID: 28070598.
    View in: PubMed
  36. Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, Woodmansee WW, Reardon DA, Freeman GJ, Fecci PE, Laws ER, Santagata S, Dunn GP, Dunn IF. Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget. 2016 Nov 22; 7(47):76565-76576. PMID: 27655724.
    View in: PubMed
  37. Xia D, Reardon DA, Bruce JL, Lindeman NI. The Clinical Implications of Inconsistently Methylated Results from Glioblastoma MGMT Testing by Replicate Methylation-Specific PCR. J Mol Diagn. 2016 11; 18(6):864-871. PMID: 27639200.
    View in: PubMed
  38. Zhang B, Chang K, Ramkissoon S, Tanguturi S, Bi WL, Reardon DA, Ligon KL, Alexander BM, Wen PY, Huang RY. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol. 2017 01; 19(1):109-117. PMID: 27353503.
    View in: PubMed
  39. Eisele SC, Reardon DA. Adult brainstem gliomas. Cancer. 2016 09 15; 122(18):2799-809. PMID: 27327773.
    View in: PubMed
  40. Miller MB, Bi WL, Ramkissoon LA, Kang YJ, Abedalthagafi M, Knoff DS, Agarwalla PK, Wen PY, Reardon DA, Alexander BM, Laws ER, Dunn IF, Beroukhim R, Ligon KL, Ramkissoon SH. MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063. PMID: 27175596.
    View in: PubMed
  41. Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. Reply to F. Felix et al and M.F. Fay et al. J Clin Oncol. 2016 Sep 01; 34(25):3107-8. PMID: 27298403.
    View in: PubMed
  42. Bi WL, Wu WW, Santagata S, Reardon DA, Dunn IF. Checkpoint inhibition in meningiomas. Immunotherapy. 2016 06; 8(6):721-31. PMID: 27197540.
    View in: PubMed
  43. Chang K, Zhang B, Guo X, Zong M, Rahman R, Sanchez D, Winder N, Reardon DA, Zhao B, Wen PY, Huang RY. Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol. 2016 12; 18(12):1680-1687. PMID: 27257279.
    View in: PubMed
  44. Cabrera AR, Kirkpatrick JP, Fiveash JB, Shih HA, Koay EJ, Lutz S, Petit J, Chao ST, Brown PD, Vogelbaum M, Reardon DA, Chakravarti A, Wen PY, Chang E. Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2016 Jul-Aug; 6(4):217-25. PMID: 27211230.
    View in: PubMed
  45. Lee EQ, Muzikansky A, Drappatz J, Kesari S, Wong ET, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty L, Stefanik J, LaFrankie D, Ruland SF, Pulverenti J, Smith KH, Gaffey SC, Hammond S, Wen PY. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016 06; 18(6):849-54. PMID: 26902850; PMCID: PMC4864265 [Available on 06/01/17].
  46. Abedalthagafi M, Bi WL, Aizer AA, Merrill PH, Brewster R, Agarwalla PK, Listewnik ML, Dias-Santagata D, Thorner AR, Van Hummelen P, Brastianos PK, Reardon DA, Wen PY, Al-Mefty O, Ramkissoon SH, Folkerth RD, Ligon KL, Ligon AH, Alexander BM, Dunn IF, Beroukhim R, Santagata S. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55. PMID: 26826201; PMCID: PMC4827048 [Available on 05/01/17].
  47. Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. J Clin Oncol. 2016 Mar 01; 34(7):731-9. PMID: 26786929.
    View in: PubMed
  48. Wen PY, Reardon DA. Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 2016 Feb; 12(2):69-70. PMID: 26782337.
    View in: PubMed
  49. Soffietti R, Rudà R, Reardon D. Rare glial tumors. Handb Clin Neurol. 2016; 134:399-415. PMID: 26948368.
    View in: PubMed
  50. Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 2016 Feb 15; 122(4):582-7. PMID: 26588662.
    View in: PubMed
  51. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016 Feb; 4(2):124-35. PMID: 26546453.
    View in: PubMed
  52. Reardon DA, Gilbert MR, Wick W, Liau L. Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii32-vii40. PMID: 26516225; PMCID: PMC4625894 [Available on 11/01/16].
  53. Reardon DA, Weller M. Introduction. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii1. PMID: 26516220; PMCID: PMC4625895 [Available on 11/01/16].
  54. Reardon DA, Weller M. Dedication: Andrew T. Parsa. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii2. PMID: 26516222; PMCID: PMC4625896 [Available on 11/01/16].
  55. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015 Nov; 16(15):e534-e542. PMID: 26545842.
    View in: PubMed
  56. Neagu MR, Reardon DA. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Curr Treat Options Oncol. 2015 Nov; 16(11):54. PMID: 26454859.
    View in: PubMed
  57. Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81. PMID: 26490307.
    View in: PubMed
  58. Alshami J, Guiot MC, Owen S, Kavan P, Gibson N, Solca F, Cseh A, Reardon DA, Muanza T. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report. Oncotarget. 2015 Oct 20; 6(32):34030-7. PMID: 26423602; PMCID: PMC4741824.
  59. Wu WW, Bi WL, Kang YJ, Ramkissoon SH, Prasad S, Shih HA, Reardon DA, Dunn IF. Adult Atypical Teratoid/Rhabdoid Tumors. World Neurosurg. 2016 Jan; 85:197-204. PMID: 26344637.
    View in: PubMed
  60. Aizer AA, Abedalthagafi M, Bi WL, Horvath MC, Arvold ND, Al-Mefty O, Lee EQ, Nayak L, Rinne ML, Norden AD, Reardon DA, Wen PY, Ligon KL, Ligon AH, Beroukhim R, Dunn IF, Santagata S, Alexander BM. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74. PMID: 26323607; PMCID: PMC4724184 [Available on 02/01/17].
  61. Aizer AA, Bi WL, Kandola MS, Lee EQ, Nayak L, Rinne ML, Norden AD, Beroukhim R, Reardon DA, Wen PY, Al-Mefty O, Arvold ND, Dunn IF, Alexander BM. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81. PMID: 26308667.
    View in: PubMed
  62. Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015 Sep; 11(9):504-14. PMID: 26260659; PMCID: PMC4782584.
  63. Abou Al-Shaar H, Almefty KK, Abolfotoh M, Arvold ND, Devlin PM, Reardon DA, Loeffler JS, Al-Mefty O. Brachytherapy in the treatment of recurrent aggressive falcine meningiomas. J Neurooncol. 2015 Sep; 124(3):515-22. PMID: 26253325.
    View in: PubMed
  64. Reardon DA, Schuster JM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, Green J, Yellin MJ, Turner CD, Davis TA, Sampson JH. 107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma. Neurosurgery. 2015 Aug; 62 Suppl 1:198-9. PMID: 26181953.
    View in: PubMed
  65. Shankar GM, Francis JM, Rinne ML, Ramkissoon SH, Huang FW, Venteicher AS, Akama-Garren EH, Kang YJ, Lelic N, Kim JC, Brown LE, Charbonneau SK, Golby AJ, Sekhar Pedamallu C, Hoang MP, Sullivan RJ, Cherniack AD, Garraway LA, Stemmer-Rachamimov A, Reardon DA, Wen PY, Brastianos PK, Curry WT, Barker FG, Hahn WC, Nahed BV, Ligon KL, Louis DN, Cahill DP, Meyerson M. Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7. PMID: 26181761; PMCID: PMC4872045.
  66. Neagu MR, Reardon DA. Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients? Immunotherapy. 2015; 7(6):603-6. PMID: 26100271.
    View in: PubMed
  67. Rahman R, Catalano PJ, Reardon DA, Norden AD, Wen PY, Lee EQ, Nayak L, Beroukhim R, Dunn IF, Golby AJ, Johnson MD, Chiocca EA, Claus EB, Alexander BM, Arvold ND. Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46. PMID: 26033544.
    View in: PubMed
  68. Reardon DA, Ligon KL, Chiocca EA, Wen PY. One size should not fit all: advancing toward personalized glioblastoma therapy. Discov Med. 2015 Jun; 19(107):471-7. PMID: 26175405.
    View in: PubMed
  69. Peters KB, Lou E, Desjardins A, Reardon DA, Lipp ES, Miller E, Herndon JE, McSherry F, Friedman HS, Vredenburgh JJ. Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. Oncologist. 2015 Jul; 20(7):727-8. PMID: 26025933; PMCID: PMC4492239.
  70. Sridharan V, Urbanski LM, Bi WL, Thistle K, Miller MB, Ramkissoon S, Reardon DA, Dunn IF. Multicentric Low-Grade Gliomas. World Neurosurg. 2015 Oct; 84(4):1045-50. PMID: 26004698.
    View in: PubMed
  71. Vlahovic G, Fecci PE, Reardon D, Sampson JH. Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. Neuro Oncol. 2015 Aug; 17(8):1043-5. PMID: 25964311; PMCID: PMC4490880.
  72. Cleary JM, Reardon DA, Azad N, Gandhi L, Shapiro GI, Chaves J, Pedersen M, Ansell P, Ames W, Xiong H, Munasinghe W, Dudley M, Reilly EB, Holen K, Humerickhouse R. A phase 1 study of ABT-806 in subjects with advanced solid tumors. Invest New Drugs. 2015 Jun; 33(3):671-8. PMID: 25895099.
    View in: PubMed
  73. Arvold ND, Tanguturi SK, Aizer AA, Wen PY, Reardon DA, Lee EQ, Nayak L, Christianson LW, Horvath MC, Dunn IF, Golby AJ, Johnson MD, Claus EB, Chiocca EA, Ligon KL, Alexander BM. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9. PMID: 25841623.
    View in: PubMed
  74. Neagu MR, Huang RY, Reardon DA, Wen PY. How treatment monitoring is influencing treatment decisions in glioblastomas. Curr Treat Options Neurol. 2015 Apr; 17(4):343. PMID: 25749847.
    View in: PubMed
  75. Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015 May; 17(5):708-17. PMID: 25762461; PMCID: PMC4482861.
  76. Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19; 519(7543):366-9. PMID: 25762141; PMCID: PMC4510871.
  77. Du Z, Abedalthagafi M, Aizer AA, McHenry AR, Sun HH, Bray MA, Viramontes O, Machaidze R, Brastianos PK, Reardon DA, Dunn IF, Freeman GJ, Ligon KL, Carpenter AE, Alexander BM, Agar NY, Rodig SJ, Bradshaw EM, Santagata S. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015 Mar 10; 6(7):4704-16. PMID: 25609200; PMCID: PMC4467109.
  78. Ramkissoon SH, Bi WL, Schumacher SE, Ramkissoon LA, Haidar S, Knoff D, Dubuc A, Brown L, Burns M, Cryan JB, Abedalthagafi M, Kang YJ, Schultz N, Reardon DA, Lee EQ, Rinne ML, Norden AD, Nayak L, Ruland S, Doherty LM, LaFrankie DC, Horvath M, Aizer AA, Russo A, Arvold ND, Claus EB, Al-Mefty O, Johnson MD, Golby AJ, Dunn IF, Chiocca EA, Trippa L, Santagata S, Folkerth RD, Kantoff P, Rollins BJ, Lindeman NI, Wen PY, Ligon AH, Beroukhim R, Alexander BM, Ligon KL. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55. PMID: 25754088; PMCID: PMC4578577 [Available on 10/01/16].
  79. Han K, Ren M, Wick W, Abrey L, Das A, Jin J, Reardon DA. Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma. Neuro Oncol. 2015 May; 17(5):764-5. PMID: 25722425; PMCID: PMC4386660.
  80. Reardon DA, Okada H. Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neurooncol. 2015 Jul; 123(3):339-46. PMID: 25707876.
    View in: PubMed
  81. Huang RY, Neagu MR, Reardon DA, Wen PY. Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response. Front Neurol. 2015; 6:33. PMID: 25755649.
    View in: PubMed
  82. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61. PMID: 25586468; PMCID: PMC4483122.
  83. Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, Chi AS, Batchelor TT, Hempfling K, McCluskey C, Smith KH, Gaffey SC, Wrigley B, Ligon KL, Raizer JJ, Wen PY. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7. PMID: 25572329; PMCID: PMC4483124.
  84. Reardon DA, Wen PY. Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol. 2015 Feb; 12(2):69-70. PMID: 25560529.
    View in: PubMed
  85. Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6. PMID: 25527270; PMCID: PMC4335993.
  86. Chinot OL, Reardon DA. The future of antiangiogenic treatment in glioblastoma. Curr Opin Neurol. 2014 Dec; 27(6):675-82. PMID: 25313693.
    View in: PubMed
  87. Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M. Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res. 2014 Nov 15; 20(22):5612-9. PMID: 25398844; PMCID: PMC4234180.
  88. Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, Fichtel L, Silver B, Walters I, Reardon D. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma. Invest New Drugs. 2015 Feb; 33(1):247-53. PMID: 25388940.
    View in: PubMed
  89. Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol. 2015 Apr; 17(4):488-504. PMID: 25358508; PMCID: PMC4483077.
  90. Norden AD, Schiff D, Ahluwalia MS, Lesser GJ, Nayak L, Lee EQ, Rinne ML, Muzikansky A, Dietrich J, Purow B, Doherty LM, LaFrankie DC, Pulverenti JR, Rifenburg JA, Ruland SF, Smith KH, Gaffey SC, McCluskey C, Ligon KL, Reardon DA, Wen PY. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302. PMID: 25338318.
    View in: PubMed
  91. Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii7-13. PMID: 25342602; PMCID: PMC4207137.
  92. Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47. PMID: 25313237; PMCID: PMC4195530.
  93. Reardon DA, Ballman KV, Buckner JC, Chang SM, Ellingson BM. Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro Oncol. 2014 Oct; 16 Suppl 7:vii24-35. PMID: 25313236; PMCID: PMC4195531.
  94. Cryan JB, Haidar S, Ramkissoon LA, Bi WL, Knoff DS, Schultz N, Abedalthagafi M, Brown L, Wen PY, Reardon DA, Dunn IF, Folkerth RD, Santagata S, Lindeman NI, Ligon AH, Beroukhim R, Hornick JL, Alexander BM, Ligon KL, Ramkissoon SH. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92. PMID: 25257301; PMCID: PMC4226668.
  95. Field KM, Jordan JT, Wen PY, Rosenthal MA, Reardon DA. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. 2015 Apr 01; 121(7):997-1007. PMID: 25263092.
    View in: PubMed
  96. Reardon DA, Freeman G, Wu C, Chiocca EA, Wucherpfennig KW, Wen PY, Fritsch EF, Curry WT, Sampson JH, Dranoff G. Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov; 16(11):1441-58. PMID: 25190673; PMCID: PMC4201077.
  97. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014 Sep; 15(10):1100-8. PMID: 25163906.
    View in: PubMed
  98. Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, Cong J, Wind S, Eisenstat DD. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 2015 Mar; 17(3):430-9. PMID: 25140039; PMCID: PMC4483093.
  99. Kanaly CW, Mehta AI, Ding D, Hoang JK, Kranz PG, Herndon JE, Coan A, Crocker I, Waller AF, Friedman AH, Reardon DA, Sampson JH. A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma. J Neurosurg. 2014 Sep; 121(3):536-42. PMID: 25036205; PMCID: PMC4286293.
  100. Wen PY, Wen PY, Yung WK, Mellinghoff IK, Ramkissoon S, Alexander B, Rinne M, Colman H, Omuro AM, DeAngelis LM, Gilbert MR, DeGroot J, Cloughesy TF, Lee EQ, Nayak L, Chi AS, Batchelor T, Chang SM, Prados MD, Reardon DA, Ligon KL. Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47. PMID: 25165346.
    View in: PubMed
  101. Reardon DA, Gokhale P, Ligon K, Liao X, Rodig S, Zhou J, Win L, Hodi FS, Kohl NE, Freeman G. Immune checkpoint blockade for glioblastoma: preclinical activity of single agent and combinatorial therapy. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii11-iii12. PMID: 25165207.
    View in: PubMed
  102. Rahman R, Hempfling K, Norden AD, Reardon DA, Nayak L, Rinne ML, Beroukhim R, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Alexander BM, Huang RY, Wen PY, Lee EQ. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9. PMID: 24958095; PMCID: PMC4201074.
  103. Aizer AA, Arvold ND, Catalano P, Claus EB, Golby AJ, Johnson MD, Al-Mefty O, Wen PY, Reardon DA, Lee EQ, Nayak L, Rinne ML, Beroukhim R, Weiss SE, Ramkissoon SH, Abedalthagafi M, Santagata S, Dunn IF, Alexander BM. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53. PMID: 24891451; PMCID: PMC4201070.
  104. Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab. J Neurooncol. 2014 Aug; 119(1):149-58. PMID: 24805151.
    View in: PubMed
  105. Reardon DA. Update on the use of angiogenesis inhibitors in adult patients with brain tumors. Clin Adv Hematol Oncol. 2014 May; 12(5):293-303. PMID: 25003486.
    View in: PubMed
  106. Reardon DA, Wen PY. Targeted therapies: Further delineating bevacizumab's response spectrum. Nat Rev Clin Oncol. 2014 May; 11(5):243-4. PMID: 24710578.
    View in: PubMed
  107. Arvold ND, Reardon DA. Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging. 2014; 9:357-67. PMID: 24591820; PMCID: PMC3937103.
  108. Oh DS, Vredenburgh JA, Reardon DA, Prosnitz LR, Gockerman JP, Sampson JH, Kelsey CR, Kirkpatrick JP. Low-dose whole brain radiotherapy combined with radiosurgery for primary CNS lymphoma achieving partial response to induction methotrexate-based chemotherapy. J Radiosurg SBRT. 2014; 3(1):37-42. PMID: 29296383.
    View in: PubMed
  109. Han K, Ren M, Wick W, Abrey L, Das A, Jin J, Reardon DA. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014 May; 16(5):696-706. PMID: 24335699; PMCID: PMC3984546.
  110. Arrillaga-Romany I, Reardon DA, Wen PY. Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014 Feb; 23(2):199-210. PMID: 24320142.
    View in: PubMed
  111. Alexander BM, Wen PY, Trippa L, Reardon DA, Yung WK, Parmigiani G, Berry DA. Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2. Neuro Oncol. 2013 Aug; 15(8):972-8. PMID: 23857706; PMCID: PMC3714161.
  112. Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab. Cancer. 2013 Oct 01; 119(19):3479-88. PMID: 23821555.
    View in: PubMed
  113. Hegi ME, Gorlia T, Erridge S, Grujicic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Weyerbrock A, Hau P, Taphoorn MJ, Nabors LB, Reardon DA, Van Den Bent MJ, Perry JR, Hong YK, Hicking C, Picard M, Weller M. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. J Clin Oncol. 2013 Jun 20; 31(18_suppl):LBA2009. PMID: 28136055.
    View in: PubMed
  114. Reardon DA, Wucherpfennig KW, Freeman G, Wu CJ, Chiocca EA, Wen PY, Curry WT, Mitchell DA, Fecci PE, Sampson JH, Dranoff G. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun; 12(6):597-615. PMID: 23750791; PMCID: PMC3982399.
  115. Lee EQ, Nayak L, Wen PY, Reardon DA. Treatment options in newly diagnosed glioblastoma. Curr Treat Options Neurol. 2013 Jun; 15(3):281-8. PMID: 23553038.
    View in: PubMed
  116. Jiang X, Reardon DA, Desjardins A, Vredenburgh JJ, Quinn JA, Austin AD, Herndon JE, McLendon RE, Friedman HS. O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. J Neurooncol. 2013 Aug; 114(1):135-40. PMID: 23686298.
    View in: PubMed
  117. Rinne ML, Lee EQ, Nayak L, Norden AD, Beroukhim R, Wen PY, Reardon DA. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013 Jun; 18(2):137-53. PMID: 23668489.
    View in: PubMed
  118. Alexander BM, Lee EQ, Reardon DA, Wen PY. Current and future directions for Phase II trials in high-grade glioma. Expert Rev Neurother. 2013 Apr; 13(4):369-87. PMID: 23545053.
    View in: PubMed
  119. Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist. 2013; 18(3):273-80. PMID: 23485622; PMCID: PMC3607523.
  120. Villano JL, Wen PY, Lee EQ, Nayak L, Reardon DA, Rosenfeld MR. PCV for anaplastic oligodendrogliomas: back to the future or a step backwards? A point/counterpoint discussion. J Neurooncol. 2013 May; 113(1):143-7. PMID: 23479035.
    View in: PubMed
  121. Reardon DA, Groves MD, Wen PY, Nabors L, Mikkelsen T, Rosenfeld S, Raizer J, Barriuso J, McLendon RE, Suttle AB, Ma B, Curtis CM, Dar MM, de Bono J. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res. 2013 Feb 15; 19(4):900-8. PMID: 23363814.
    View in: PubMed
  122. Lou E, Peters KB, Sumrall AL, Desjardins A, Reardon DA, Lipp ES, Herndon JE, Coan A, Bailey L, Turner S, Friedman HS, Vredenburgh JJ. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med. 2013 Apr; 2(2):185-95. PMID: 23634286; PMCID: PMC3639657.
  123. de Groot J, Reardon DA, Batchelor TT. Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714460.
    View in: PubMed
  124. Keir ST, Friedman HS, Reardon DA, Bigner DD, Gray LA. Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. J Neurooncol. 2013 Jan; 111(2):97-102. PMID: 23086436.
    View in: PubMed
  125. Reardon DA, Herndon JE, Peters KB, Desjardins A, Coan A, Lou E, Sumrall AL, Turner S, Lipp ES, Sathornsumetee S, Rich JN, Sampson JH, Friedman AH, Boulton ST, Bigner DD, Friedman HS, Vredenburgh JJ. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer. 2012 Oct 23; 107(9):1481-7. PMID: 23037712; PMCID: PMC3493761.
  126. Nghiemphu PL, Lai A, Green RM, Reardon DA, Cloughesy T. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. J Neurooncol. 2012 Nov; 110(2):245-50. PMID: 22918789; PMCID: PMC3472078.
  127. Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. Leuk Lymphoma. 2013 Jan; 54(1):58-61. PMID: 22656234; PMCID: PMC4802006.
  128. Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 Jul; 14(7):819-29. PMID: 22619466; PMCID: PMC3379803.
  129. Reardon DA. Treatment of elderly patients with glioblastoma. Lancet Oncol. 2012 Jul; 13(7):656-7. PMID: 22578792.
    View in: PubMed
  130. Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204. PMID: 22554547.
    View in: PubMed
  131. Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, McLendon RE, Herndon JE, McSherry F, Norfleet J, Friedman HS, Reardon DA. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug; 109(1):63-70. PMID: 22535433; PMCID: PMC3404217.
  132. Chamberlain MC, Cloughsey T, Reardon DA, Wen PY. A novel treatment for glioblastoma: integrin inhibition. Expert Rev Neurother. 2012 Apr; 12(4):421-35. PMID: 22449214.
    View in: PubMed
  133. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71. PMID: 22588883; PMCID: PMC3354723.
  134. Reardon DA, Vredenburgh JJ, Desjardins A, Peters KB, Sathornsumetee S, Threatt S, Sampson JH, Herndon JE, Coan A, McSherry F, Rich JN, McLendon RE, Zhang S, Friedman HS. Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma. J Neurooncol. 2012 Jul; 108(3):499-506. PMID: 22407177; PMCID: PMC3690584.
  135. Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1507-18. PMID: 22392572; PMCID: PMC4351868.
  136. Sampson JH, Schmittling RJ, Archer GE, Congdon KL, Nair SK, Reap EA, Desjardins A, Friedman AH, Friedman HS, Herndon JE, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Mitchell DA. A pilot study of IL-2Ra blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PLoS One. 2012; 7(2):e31046. PMID: 22383993; PMCID: PMC3288003.
  137. Reardon DA, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Gururangan S, Peters KB, McLendon R, Sathornsumetee S, Rich JN, Lipp ES, Janney D, Friedman HS. Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer. 2012 Oct 01; 118(19):4759-67. PMID: 22371319; PMCID: PMC3748946.
  138. Reardon DA, Cheresh D. Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer. 2011 Dec; 2(12):1159-65. PMID: 22866207; PMCID: PMC3411133.
  139. Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA. Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60. PMID: 22037923.
    View in: PubMed
  140. Reardon DA, Herndon JE, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol. 2012 Mar; 107(1):213-21. PMID: 21997879; PMCID: PMC3403724.
  141. Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol. 2012 Mar; 107(1):155-64. PMID: 21986722; PMCID: PMC3616617.
  142. Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol. 2012 Jan; 69(1):281-7. PMID: 21984222.
    View in: PubMed
  143. Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan; 106(2):409-15. PMID: 21938530; PMCID: PMC3616615.
  144. Lou E, Turner S, Sumrall A, Reardon DA, Desjardins A, Peters KB, Sampson JH, Friedman HS, Vredenburgh JJ. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol. 2011 Oct 01; 29(28):e739-42. PMID: 21900098.
    View in: PubMed
  145. Sampson JH, Brady M, Raghavan R, Mehta AI, Friedman AH, Reardon DA, Petry NA, Barboriak DP, Wong TZ, Zalutsky MR, Lally-Goss D, Bigner DD. Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery. 2011 Sep; 69(3):668-76. PMID: 21430586; PMCID: PMC3154565.
  146. Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA. Everolimus tablets for patients with subependymal giant cell astrocytoma. Expert Opin Pharmacother. 2011 Oct; 12(14):2265-9. PMID: 21806479; PMCID: PMC3389821.
  147. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2012 Mar 01; 118(5):1302-12. PMID: 21792866.
    View in: PubMed
  148. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3. PMID: 21768451; PMCID: PMC4836609.
  149. Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH. Monoclonal antibody blockade of IL-2 receptor a during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011 Sep 15; 118(11):3003-12. PMID: 21768296; PMCID: PMC3175779.
  150. Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, Friedman HS. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol. 2011 Dec; 105(3):621-7. PMID: 21744079; PMCID: PMC3748953.
  151. Desjardins A, Reardon DA, Peters KB, Threatt S, Coan AD, Herndon JE, Friedman AH, Friedman HS, Vredenburgh JJ. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma. J Neurooncol. 2011 Dec; 105(3):601-6. PMID: 21735117.
    View in: PubMed
  152. Ruden E, Reardon DA, Coan AD, Herndon JE, Hornsby WE, West M, Fels DR, Desjardins A, Vredenburgh JJ, Waner E, Friedman AH, Friedman HS, Peters KB, Jones LW. Exercise behavior, functional capacity, and survival in adults with malignant recurrent glioma. J Clin Oncol. 2011 Jul 20; 29(21):2918-23. PMID: 21690470; PMCID: PMC3138718.
  153. Reardon DA, Perry JR, Brandes AA, Jalali R, Wick W. Advances in malignant glioma drug discovery. Expert Opin Drug Discov. 2011 Jul; 6(7):739-53. PMID: 22650980.
    View in: PubMed
  154. Eisenstat DD, Nabors LB, Mason WP, Perry JR, Shapiro WR, Kavan P, Phuphanich S, Fu Y, Cong XJ, Shahidi M, Reardon DA. A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2010. PMID: 28023857.
    View in: PubMed
  155. Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Lamborn K, Wen PY, Prados M, DeAngelis LM, Omuro AM. Multicenter phase II trial of temozolomide (TMZ) and rituximab (RIT) for recurrent primary CNS lymphoma (PCNSL): North American Brain Tumor Consortium (NABTC) study 05-01. J Clin Oncol. 2011 May 20; 29(15_suppl):2039. PMID: 28023834.
    View in: PubMed
  156. Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Kirkpatrick J, Coan AD, Bailey L, Janney D, Lu C, Friedman HS. Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM). J Clin Oncol. 2011 May 20; 29(15_suppl):2098. PMID: 28019863.
    View in: PubMed
  157. Norden AD, Hammond S, Drappatz J, Phuphanich S, Reardon DA, Wong E, Plotkin SR, Lesser GJ, Raizer JJ, Batchelor T, Quant EC, Beroukhim R, Kaley TJ, Muzikansky A, Ciampa AS, Doherty LM, Smith KH, Gerard M, Sceppa C, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040. PMID: 28023794.
    View in: PubMed
  158. Cuneo KC, Cabrera AR, Sampson JH, Allen KJ, Vredenburgh JJ, Peters K, Chang Z, Herndon JE, Desjardins A, Reardon DA, Kirkpatrick J. Safety results from a prospective study of concurrent radiosurgery and bevacizumab for recurrent malignant glioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2082. PMID: 28019873.
    View in: PubMed
  159. Sumrall AL, Reardon DA, Desjardins A, Peters K, Lou E, Turner SG, Bailey L, Friedman HS, Vredenburgh JJ. Venous thromboembolic complications in patients with malignant glioma treated on a bevacizumab clinical trial. J Clin Oncol. 2011 May 20; 29(15_suppl):9090. PMID: 28021530.
    View in: PubMed
  160. Lou E, Reardon DA, Peters K, Desjardins A, Herndon JE, Coan AD, Turner SG, Sumrall AL, Bailey L, Friedman HS, Vredenburgh JJ. Upfront bevacizumab with temozolomide or with temozolomide and irinotecan for unresectable or multifocal glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2055. PMID: 28019946.
    View in: PubMed
  161. Bota DA, Eroglu Z, Reardon DA, Fu BD, Norfleet J, Desjardins A, Linskey ME, Peters K, Friedman HS, Vredenburgh JJ. Phase II clinical trial of bortezomib and bevacizumab combination in recurrent glioblastoma. J Clin Oncol. 2011 May 20; 29(15_suppl):2056. PMID: 28019947.
    View in: PubMed
  162. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Coan AD, Herndon JE, Friedman HS. Bevacizumab (BV) continuation following BV progression: Meta-analysis of five consecutive recurrent glioblastoma (GBM) trials. J Clin Oncol. 2011 May 20; 29(15_suppl):2030. PMID: 28023816.
    View in: PubMed
  163. Desjardins A, Reardon DA, Vredenburgh JJ, Peters K, Trikha M, James J, Gardner M, Brickhouse A, Herndon JE, Friedman HS. A pharmacokinetic (PK) study of AC480 administered twice daily in patients with surgically resectable, recurrent malignant glioma (MG) not on enzyme-inducing antiepileptic drug (EIAED). J Clin Oncol. 2011 May 20; 29(15_suppl):2070. PMID: 28019891.
    View in: PubMed
  164. Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Coan A, Threatt S, Friedman AH, Friedman HS. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 2011 Dec 01; 117(23):5351-8. PMID: 21590689; PMCID: PMC3158844.
  165. Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011 Jun 15; 17(12):4119-24. PMID: 21531816; PMCID: PMC3117928.
  166. Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):2018-24. PMID: 21489708; PMCID: PMC3690566.
  167. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011 Jun; 12(6):583-93. PMID: 21474379.
    View in: PubMed
  168. Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS. A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw. 2011 Apr; 9(4):414-27. PMID: 21464146; PMCID: PMC3399727.
  169. Simao LM, Dine Sultan EN, Hall JK, Reardon DA, Bhatti MT. Knee deep in the nerve. Surv Ophthalmol. 2011 Jul-Aug; 56(4):362-70. PMID: 21371729.
    View in: PubMed
  170. Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide a?ß3 and a?ß5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011 Mar; 7(3):339-54. PMID: 21417900.
    View in: PubMed
  171. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61. PMID: 21310734; PMCID: PMC3064608.
  172. Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr; 13(4):437-46. PMID: 21297127; PMCID: PMC3064694.
  173. Galanis E, Wu W, Sarkaria J, Chang SM, Colman H, Sargent D, Reardon DA. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep. 2011 Feb; 13(1):42-9. PMID: 21125354; PMCID: PMC3155285.
  174. Kanaly CW, Ding D, Mehta AI, Waller AF, Crocker I, Desjardins A, Reardon DA, Friedman AH, Bigner DD, Sampson JH. A novel method for volumetric MRI response assessment of enhancing brain tumors. PLoS One. 2011 Jan 26; 6(1):e16031. PMID: 21298088; PMCID: PMC3027624.
  175. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar; 13(3):324-33. PMID: 21149254; PMCID: PMC3064599.
  176. Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE, Marcello J, Bailey L, Threatt S, Sampson J, Friedman A, Friedman HS. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):58-66. PMID: 21036490.
    View in: PubMed
  177. Paldino MJ, Wong TZ, Reardon DA, Friedman HS, Barboriak DP. Prognostic significance of parameters derived from co-registered 18F-fluorodeoxyglucose PET and contrast-enhanced MRI in patients with high-grade glioma. Br J Radiol. 2011 Apr; 84(1000):327-33. PMID: 20959370; PMCID: PMC3473471.
  178. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 01; 28(31):4722-9. PMID: 20921459; PMCID: PMC3020702.
  179. Reardon DA, Desjardins A, Peters K, Gururangan S, Sampson J, Rich JN, McLendon R, Herndon JE, Marcello J, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol. 2011 Jun; 103(2):371-9. PMID: 20853132; PMCID: PMC3102515.
  180. Mattox A, Hughes B, Oleson J, Reardon D, McLendon R, Adamson C. Treatment recommendations for primary extradural meningiomas. Cancer. 2011 Jan 01; 117(1):24-38. PMID: 20824719.
    View in: PubMed
  181. Tabatabai G, Weller M, Nabors B, Picard M, Reardon D, Mikkelsen T, Ruegg C, Stupp R. Targeting integrins in malignant glioma. Target Oncol. 2010 Sep; 5(3):175-81. PMID: 20820929.
    View in: PubMed
  182. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, Gururangan S, Friedman HS, Reardon DA. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010 Dec; 12(12):1300-10. PMID: 20716591; PMCID: PMC3018944.
  183. Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, Rodríguez-Ponce MI, Chang SM, Mittermeyer S, Croteau D, Puri RK. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg. 2010 Aug; 113(2):301-9. PMID: 20020841.
    View in: PubMed
  184. Ellis LM, Reardon DA. Is there really a yin and yang to VEGF-targeted therapies? Lancet Oncol. 2010 Sep; 11(9):809-11. PMID: 20634133.
    View in: PubMed
  185. Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol. 2010 Oct; 12(10):1061-70. PMID: 20615922; PMCID: PMC3018931.
  186. Neyns B, Tosoni A, Hwu WJ, Reardon DA. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010 Jun 15; 116(12):2868-77. PMID: 20564393.
    View in: PubMed
  187. Peters KB, Coyle TE, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA. Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapy. J Neurooncol. 2011 Jan; 101(1):155-9. PMID: 20524043.
    View in: PubMed
  188. Jones LW, Mourtzakis M, Peters KB, Friedman AH, West MJ, Mabe SK, Kraus WE, Friedman HS, Reardon DA. Changes in functional performance measures in adults undergoing chemoradiation for primary malignant glioma: a feasibility study. Oncologist. 2010; 15(6):636-47. PMID: 20484122; PMCID: PMC3227991.
  189. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE, McLendon RE, Janney D, Friedman AH, Bigner DD, Friedman HS. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. J Neurooncol. 2011 Jan; 101(1):57-66. PMID: 20443129; PMCID: PMC3102498.
  190. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72. PMID: 20231676.
    View in: PubMed
  191. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010 Apr; 11(4):373-82. PMID: 20171141.
    View in: PubMed
  192. Jones LW, Friedman AH, West MJ, Mabe SK, Fraser J, Kraus WE, Friedman HS, Tresch MI, Major N, Reardon DA. Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. Cancer. 2010 Feb 01; 116(3):695-704. PMID: 20029975; PMCID: PMC2815124.
  193. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, Sathornsumetee S, McLendon RE, Herndon JE, Marcello JE, Norfleet J, Friedman AH, Bigner DD, Friedman HS. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009 Dec 15; 101(12):1986-94. PMID: 19920819; PMCID: PMC2795427.
  194. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009 Dec 15; 101(12):1995-2004. PMID: 19904263; PMCID: PMC2795431.
  195. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, Lally-Goss D, McGehee-Norman S, Paolino A, Reardon DA, Friedman AH, Friedman HS, Bigner DD. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009 Oct; 8(10):2773-9. PMID: 19825799; PMCID: PMC2991139.
  196. Affronti ML, Heery CR, Herndon JE, Rich JN, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Bigner DD, Friedman HS. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009 Aug 01; 115(15):3501-11. PMID: 19514083.
    View in: PubMed
  197. Desjardins A, Reardon DA, Vredenburgh JJ. Current available therapies and future directions in the treatment of malignant gliomas. Biologics. 2009; 3:15-25. PMID: 19707392; PMCID: PMC2726053.
  198. Weller M, Reardon D, Nabors B, Stupp R. Will integrin inhibitors have proangiogenic effects in the clinic? Nat Med. 2009 Jul; 15(7):726; author reply 727. PMID: 19584855.
    View in: PubMed
  199. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Friedman HS. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer. 2009 Jul 01; 115(13):2964-70. PMID: 19402172; PMCID: PMC2748258.
  200. Reardon DA, Desjardins A, Vredenburgh JJ, Gururangan S, Friedman AH, Herndon JE, Marcello J, Norfleet JA, McLendon RE, Sampson JH, Friedman HS. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 2010 Jan; 96(2):219-30. PMID: 19562254; PMCID: PMC2844073.
  201. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman AH, Sampson JH, McLendon RE, Herndon JE, Friedman HS. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J Neurooncol. 2009 Dec; 95(3):393-400. PMID: 19533023; PMCID: PMC2835159.
  202. Vredenburgh JJ, Desjardins A, Reardon DA, Peters K, Herndon JE, Kirkpatrick J, Gururangan S, Bailey L, Friedman AH, Friedman HS. Safety and efficacy of the addition of bevacizumab (BV) to temozolomide (TMZ) and radiation therapy (RT) followed by BV, TMZ, and irinotecan (CPT-11) for newly diagnosed glioblastoma multiforme (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):2015. PMID: 27964581.
    View in: PubMed
  203. Herndon J, Vredenburgh J, Reardon D, Desjardins A, Peters K, Gururangan S, Norfleet J, Friedman A, Bigner D, Friedman HS. Phase I trial of vendetanib and oral etoposide for recurrent malignant gliomas. J Clin Oncol. 2009 May 20; 27(15_suppl):e13016. PMID: 27962830.
    View in: PubMed
  204. Desjardins A, Reardon DA, Gururangan S, Peters K, Threatt S, Friedman A, Friedman H, Vredenburgh J. Phase I trial combining SCH 66336 to temozolomide (TMZ) for patients with grade 3 or 4 malignant gliomas (MG). J Clin Oncol. 2009 May 20; 27(15_suppl):e13004. PMID: 27962751.
    View in: PubMed
  205. Reardon D, Desjardins A, Vredenburgh JJ, Gururangan S, Peters KB, Norfleet JA. Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results. J Clin Oncol. 2009 May 20; 27(15_suppl):2046. PMID: 27964642.
    View in: PubMed
  206. Jones L, Friedman A, West M, Mabe S, Fraser J, Kraus W, Friedman H, Major N, Reardon D. Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13002. PMID: 27962755.
    View in: PubMed
  207. Frentzas SN, Groves MD, Barriuso J, Harris D, Reardon D, Curtis MC, Suttle AB, Ma B, Lager JJ, de Bono JS. Pazopanib and lapatinib in patients with relapsed malignant glioma: Results of a phase I/II study. J Clin Oncol. 2009 May 20; 27(15_suppl):2040. PMID: 27964651.
    View in: PubMed
  208. Kirkpatrick JP, Vredenburgh JJ, Desjardins A, Gururangan S, Peters KB, Boulton ST, Friedman AH, Friedman HS, Reardon DA. Phase I study of vandetanib, imatinib mesylate, and hydroxyurea for recurrent malignant glioma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13007. PMID: 27962760.
    View in: PubMed
  209. Friedman HS, Vredenburgh JJ, Desjardins A, Janney DE, Peters KB, Friedman AH, Gururangan S, Reardon DA. A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent malignant glioma. J Clin Oncol. 2009 May 20; 27(15_suppl):e13024. PMID: 27962793.
    View in: PubMed
  210. Sathornsumetee S, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Friedman HS, Reardon DA. Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas. J Clin Oncol. 2009 May 20; 27(15_suppl):2045. PMID: 27964647.
    View in: PubMed
  211. Peters K, Desjardins A, Reardon DA, Perry S, Herndon JE, Bailey L, Friedman AH, Friedman HS, Bigner DD, Vredenburgh JJ. Temozolomide (TMZ) and bevacizumab (BV) as initial treatment for unresectable or multifocal glioblastoma multiforme (GBM). J Clin Oncol. 2009 May 20; 27(15_suppl):e13025. PMID: 27962792.
    View in: PubMed
  212. Sampson JH, Archer GE, Bigner DD, Schmittling RJ, Herndon JE, Davis T, Friedman HS, Keler T, Reardon DA, Mitchell DA. Effect of daclizumab on TReg counts and EGFRvIII-specific immune responses in GBM. J Clin Oncol. 2009 May 20; 27(15_suppl):2034. PMID: 27964629.
    View in: PubMed
  213. Heimberger AB, Archer GE, Mitchell DA, Bigner DD, Schmittling RJ, Herndon JE, Davis T, Friedman HS, Keler T, Reardon DA, Sampson JH. Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. J Clin Oncol. 2009 May 20; 27(15_suppl):2021. PMID: 27964605.
    View in: PubMed
  214. Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE, Salvado AJ, Friedman HS. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 2009 May 15; 115(10):2188-98. PMID: 19248046; PMCID: PMC2691174.
  215. Perry SL, Bohlin C, Reardon DA, Desjardins A, Friedman AH, Friedman HS, Vredenburgh JJ. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol. 2009 Oct; 95(1):129-134. PMID: 19415455; PMCID: PMC2837514.
  216. Ellis LM, Reardon DA. Cancer: The nuances of therapy. Nature. 2009 Mar 19; 458(7236):290-2. PMID: 19295595.
    View in: PubMed
  217. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma. Neuro Oncol. 2009 Oct; 11(5):556-61. PMID: 19289491; PMCID: PMC2765345.
  218. Sathornsumetee S, Reardon DA. Targeting multiple kinases in glioblastoma multiforme. Expert Opin Investig Drugs. 2009 Mar; 18(3):277-92. PMID: 19243279.
    View in: PubMed
  219. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb 19; 360(8):765-73. PMID: 19228619; PMCID: PMC2820383.
  220. Jones LW, Cohen RR, Mabe SK, West MJ, Desjardins A, Vredenburgh JJ, Friedman AH, Reardon DA, Waner E, Friedman HS. Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. J Neurooncol. 2009 Aug; 94(1):79-85. PMID: 19212703.
    View in: PubMed
  221. Quinn JA, Jiang SX, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Walker A, Friedman HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10; 27(8):1262-7. PMID: 19204199; PMCID: PMC2667825.
  222. Quinn JA, Jiang SX, Carter J, Reardon DA, Desjardins A, Vredenburgh JJ, Rich JN, Gururangan S, Friedman AH, Bigner DD, Sampson JH, McLendon RE, Herndon JE, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res. 2009 Feb 01; 15(3):1064-8. PMID: 19188181; PMCID: PMC2710963.
  223. Bullitt E, Ewend M, Vredenburgh J, Friedman A, Lin W, Wilber K, Zeng D, Aylward SR, Reardon D. Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years. Neuroimage. 2009 Aug; 47 Suppl 2:T143-51. PMID: 19103295; PMCID: PMC2752720.
  224. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008 Dec 01; 26(34):5610-7. PMID: 18981465.
    View in: PubMed
  225. Desjardins A, Reardon DA, Herndon JE, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res. 2008 Nov 01; 14(21):7068-73. PMID: 18981004; PMCID: PMC3671765.
  226. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009 Feb; 11(1):80-91. PMID: 18784279; PMCID: PMC2718962.
  227. Gururangan S, Krauser J, Watral MA, Driscoll T, Larrier N, Reardon DA, Rich JN, Quinn JA, Vredenburgh JJ, Desjardins A, McLendon RE, Fuchs H, Kurtzberg J, Friedman HS. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma. Neuro Oncol. 2008 Oct; 10(5):745-51. PMID: 18755919; PMCID: PMC2666251.
  228. Reardon DA, Nabors LB, Stupp R, Mikkelsen T. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs. 2008 Aug; 17(8):1225-35. PMID: 18616418; PMCID: PMC2832832.
  229. Wagner SA, Desjardins A, Reardon DA, Marcello J, Herndon JE, Quinn JA, Rich JN, Sathornsumetee S, Friedman HS, Vredenburgh JJ. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas. J Clin Oncol. 2008 May 20; 26(15_suppl):2021. PMID: 27948074.
    View in: PubMed
  230. Kirkpatrick JP, Rich JN, Vredenburgh JJ, Desjardins A, Quinn JA, Gururangan S, Sathornsumetee S, Egorin MJ, Friedman HS, Reardon DA. Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG). J Clin Oncol. 2008 May 20; 26(15_suppl):2057. PMID: 27948101.
    View in: PubMed
  231. Desjardins A, Barboriak DP, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Friedman HS, Vredenburgh JJ. Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients. J Clin Oncol. 2008 May 20; 26(15_suppl):2026. PMID: 27948081.
    View in: PubMed
  232. Sathornsumetee S, Vredenburgh JJ, Rich JN, Desjardins A, Quinn JA, Mathe AE, Gururangan S, Friedman AH, Friedman HS, Reardon DA. Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):13008. PMID: 27951228.
    View in: PubMed
  233. Sampson JH, Archer GE, Bigner DD, Davis T, Friedman HS, Keler T, Mitchell DA, Reardon DA, Sawaya R, Heimberger AB. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J Clin Oncol. 2008 May 20; 26(15_suppl):2011. PMID: 27948414.
    View in: PubMed
  234. Salacz ME, Desjardins A, Quinn JA, Rich JN, Vredenburgh JJ, Sathornsumetee S, Goli K, Friedman HS, Reardon DA. Treatment of adults with recurrent progressive low-grade glioma using imatinib mesylate and hydroxyurea. J Clin Oncol. 2008 May 20; 26(15_suppl):2071. PMID: 27948020.
    View in: PubMed
  235. Mitchell D, Archer GE, Bigner DD, Friedman HS, Lally-Goss D, Herndon JE, McGehee S, McLendon R, Reardon DA, Sampson JH. Efficacy of a phase II vaccine targeting Cytomegalovirus antigens in newly diagnosed GBM. J Clin Oncol. 2008 May 20; 26(15_suppl):2042. PMID: 27948118.
    View in: PubMed
  236. Quinn JA, Jiang XS, Rich JN, Desjardins A, Vredenburgh JJ, Reardon DA, Gururangan S, Walker AR, Birch R, Friedman AH, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine on three different 5-day temozolomide regimens for patients with progressive glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):2084. PMID: 27948044.
    View in: PubMed
  237. Maron R, Vredenburgh JJ, Desjardins A, Reardon DA, Quinn JA, Rich JN, Gururangan S, Wagner SA, Salacz ME, Friedman HS. Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2008 May 20; 26(15_suppl):2074. PMID: 27947970.
    View in: PubMed
  238. Reardon DA, Cloughsey TF, Raizer JJ, Laterra J, Schiff D, Yang X, Loh E, Wen PY. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. J Clin Oncol. 2008 May 20; 26(15_suppl):2051. PMID: 27948095.
    View in: PubMed
  239. Everson RG, Graner MW, Gromeier M, Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS, Friedman AH, Bigner DD, Sampson JH. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Expert Rev Anticancer Ther. 2008 May; 8(5):717-32. PMID: 18471045.
    View in: PubMed
  240. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JE, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008 Jun; 10(3):320-9. PMID: 18403491; PMCID: PMC2563054.
  241. Reardon DA, Wen PY, Desjardins A, Batchelor TT, Vredenburgh JJ. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther. 2008 Apr; 8(4):541-53. PMID: 18352856; PMCID: PMC2871667.
  242. Reardon DA, Desjardins A, Vredenburgh JJ, Sathornsumetee S, Rich JN, Quinn JA, Lagattuta TF, Egorin MJ, Gururangan S, McLendon R, Herndon JE, Friedman AH, Salvado AJ, Friedman HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol. 2008 Jun; 10(3):330-40. PMID: 18359865; PMCID: PMC2563055.
  243. Reardon DA, Zalutsky MR, Akabani G, Coleman RE, Friedman AH, Herndon JE, McLendon RE, Pegram CN, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Guruangan S, Boulton S, Raynor RH, Dowell JM, Wong TZ, Zhao XG, Friedman HS, Bigner DD. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol. 2008 Apr; 10(2):182-9. PMID: 18287339; PMCID: PMC2613820.
  244. Reardon DA, Desjardins A, Rich JN, Vredenburgh JJ. The emerging role of anti-angiogenic therapy for malignant glioma. Curr Treat Options Oncol. 2008 Feb; 9(1):1-22. PMID: 18256938.
    View in: PubMed
  245. Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med. 2008 Jan; 49(1):30-8. PMID: 18077533; PMCID: PMC2832604.
  246. Gururangan S, Frankel W, Broaddus R, Clendenning M, Senter L, McDonald M, Eastwood J, Reardon D, Vredenburgh J, Quinn J, Friedman HS. Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation. Neuro Oncol. 2008 Feb; 10(1):93-7. PMID: 17993636; PMCID: PMC2600843.
  247. Sathornsumetee S, Rich JN, Reardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin. 2007 Nov; 25(4):1111-39, x. PMID: 17964028.
    View in: PubMed
  248. Vredenburgh JJ, Desjardins A, Herndon JE, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007 Oct 20; 25(30):4722-9. PMID: 17947719.
    View in: PubMed
  249. Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer. 2007 Jul 01; 110(1):13-24. PMID: 17520692.
    View in: PubMed
  250. Zalutsky MR, Reardon DA, Pozzi OR, Vaidyanathan G, Bigner DD. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies. Nucl Med Biol. 2007 Oct; 34(7):779-85. PMID: 17921029; PMCID: PMC2083568.
  251. Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther. 2007 May; 7(5):675-87. PMID: 17492931.
    View in: PubMed
  252. Bullitt E, Reardon DA, Smith JK. A review of micro- and macrovascular analyses in the assessment of tumor-associated vasculature as visualized by MR. Neuroimage. 2007; 37 Suppl 1:S116-9. PMID: 17512217; PMCID: PMC2292206.
  253. Sampson JH, Raghavan R, Brady ML, Provenzale JM, Herndon JE, Croteau D, Friedman AH, Reardon DA, Coleman RE, Wong T, Bigner DD, Pastan I, Rodríguez-Ponce MI, Tanner P, Puri R, Pedain C. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol. 2007 Jul; 9(3):343-53. PMID: 17435179; PMCID: PMC1907410.
  254. McLendon RE, Akabani G, Friedman HS, Reardon DA, Cleveland L, Cokgor I, Herndon JE, Wikstrand C, Boulton ST, Friedman AH, Bigner DD, Zalutsky MR. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol. 2007 May; 34(4):405-13. PMID: 17499730; PMCID: PMC1952684.
  255. Sathornsumetee S, DesJardins A, Reardon DA, Rich JN, Vredenburgh JJ. Neurofibromatosis type 2. Neurology. 2007 Mar 27; 68(13):E14. PMID: 17389295.
    View in: PubMed
  256. Gururangan S, Fisher MJ, Allen JC, Herndon JE, Quinn JA, Reardon DA, Vredenburgh JJ, Desjardins A, Phillips PC, Watral MA, Krauser JM, Friedman AH, Friedman HS. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007 Apr; 9(2):161-8. PMID: 17347491; PMCID: PMC1871667.
  257. Jones LW, Guill B, Keir ST, Carter K, Friedman HS, Bigner DD, Reardon DA. Using the theory of planned behavior to understand the determinants of exercise intention in patients diagnosed with primary brain cancer. Psychooncology. 2007 Mar; 16(3):232-40. PMID: 16929468.
    View in: PubMed
  258. Sampson JH, Raghavan R, Provenzale JM, Croteau D, Reardon DA, Coleman RE, Rodríguez Ponce I, Pastan I, Puri RK, Pedain C. Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin. AJR Am J Roentgenol. 2007 Mar; 188(3):703-9. PMID: 17312057.
    View in: PubMed
  259. Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007 Feb 15; 13(4):1253-9. PMID: 17317837.
    View in: PubMed
  260. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007 May; 83(1):53-60. PMID: 17245623.
    View in: PubMed
  261. Badruddoja MA, Penne K, Desjardins A, Reardon DA, Rich JN, Quinn JA, Sathornsumetee S, Friedman AH, Bigner DD, Herndon JE, Cahill A, Friedman HS, Vredenburgh JJ. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro Oncol. 2007 Jan; 9(1):70-4. PMID: 17108065; PMCID: PMC1828104.
  262. Yamamoto Y, Wong TZ, Turkington TG, Hawk TC, Reardon DA, Coleman RE. 3'-Deoxy-3'-[F-18]fluorothymidine positron emission tomography in patients with recurrent glioblastoma multiforme: comparison with Gd-DTPA enhanced magnetic resonance imaging. Mol Imaging Biol. 2006 Nov-Dec; 8(6):340-7. PMID: 17051323.
    View in: PubMed
  263. Jones LW, Guill B, Keir ST, Carter K, Friedman HS, Bigner DD, Reardon DA. Exercise interest and preferences among patients diagnosed with primary brain cancer. Support Care Cancer. 2007 Jan; 15(1):47-55. PMID: 16819629.
    View in: PubMed
  264. Heimberger AB, Hussain SF, Aldape K, Sawaya R, Archer GA, Friedman H, Reardon D, Friedman A, Bigner D, Sampson JH. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. J Clin Oncol. 2006 Jun 20; 24(18_suppl):2529. PMID: 27955024.
    View in: PubMed
  265. Vredenburgh JJ, Bohlin C, Reardon DA, Desjardins A, Quinn J, Rich J, Sathornsumetee S, Marks LB, Friedman AH, Friedman HS. Tinzaparin prophylaxis against thromboembolic complications in brain tumor patients. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1539. PMID: 27952290.
    View in: PubMed
  266. Sathornsumetee S, Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Egorin M, Salvado A, Friedman HS. An update on phase I study of dose-escalating imatinib mesylate plus standard-dosed temozolomide for the treatment of patients with malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1560. PMID: 27952499.
    View in: PubMed
  267. Desjardins A, Reardon DA, Quinn JA, Rich JN, Vredenburgh JJ, Sathornsumetee S, Salvado A, Friedman HS. Phase II trial of imatinib mesylate and hydroxyurea for grade III malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1573. PMID: 27952528.
    View in: PubMed
  268. Kirkpatrick J, Desjardins A, Vredenburgh JJ, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Friedman AH, Friedman HS, Reardon DA. Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and temozolomide: Study of cases. J Clin Oncol. 2006 Jun 20; 24(18_suppl):11522. PMID: 27954538.
    View in: PubMed
  269. Reardon D, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Gururangan S, Egorin MJ, Salvado A, Friedman HS. A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1580. PMID: 27952508.
    View in: PubMed
  270. Quinn JA, Vredenburgh JJ, Rich JN, Reardon DA, Desjardins A, Gururangan S, Friedman AH, Lavin K, Sathornsumetee S, Threatt S, Friedman HS. Phase II trial of Gliadel plus O6-benzylguanine (O6-BG) for patients with recurrent glioblastoma multiforme. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1568. PMID: 27952495.
    View in: PubMed
  271. Heery CR, Desjardins A, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Friedman AH, Reardon DA, Friedman HS. Acute toxicity analysis of patients receiving surgery, Gliadel wafer implantation, and postoperative daily temozolomide with radiation therapy for primary high-grade glioma. J Clin Oncol. 2006 Jun 20; 24(18_suppl):11504. PMID: 27954360.
    View in: PubMed
  272. Vredenburgh JJ, Desjardins A, Herndon JE, Quinn J, Rich J, Sathornsumetee S, Friedman HS, Reardon D, Gururangan S, Friedman A. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):1506. PMID: 27952313.
    View in: PubMed
  273. Reardon DA, Quinn JA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Dowell JM, Rich JN, Vredenburgh JJ, Desjardins A, Sampson JH, Gururangan S, Wong TZ, Badruddoja MA, Zhao XG, Bigner DD, Zalutsky MR. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. J Nucl Med. 2006 Jun; 47(6):912-8. PMID: 16741299.
    View in: PubMed
  274. Jones LW, Guill B, Keir ST, Carter B S K, Friedman HS, Bigner DD, Reardon DA. Patterns of exercise across the cancer trajectory in brain tumor patients. Cancer. 2006 May 15; 106(10):2224-32. PMID: 16586497.
    View in: PubMed
  275. Gururangan S, McLaughlin CA, Brashears J, Watral MA, Provenzale J, Coleman RE, Halperin EC, Quinn J, Reardon D, Vredenburgh J, Friedman A, Friedman HS. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol. 2006 Apr; 77(2):207-12. PMID: 16568209.
    View in: PubMed
  276. Kuan CT, Wakiya K, Dowell JM, Herndon JE, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):1970-82. PMID: 16609006.
    View in: PubMed
  277. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol. 2006 Mar 10; 24(8):1253-65. PMID: 16525180.
    View in: PubMed
  278. Reardon DA, Quinn JA, Vredenburgh JJ, Gururangan S, Friedman AH, Desjardins A, Sathornsumetee S, Herndon JE, Dowell JM, McLendon RE, Provenzale JM, Sampson JH, Smith RP, Swaisland AJ, Ochs JS, Lyons P, Tourt-Uhlig S, Bigner DD, Friedman HS, Rich JN. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):860-8. PMID: 16467100.
    View in: PubMed
  279. Reardon DA, Wen PY. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist. 2006 Feb; 11(2):152-64. PMID: 16476836.
    View in: PubMed
  280. Reardon DA. Glioblastoma--more questions than answers? Nat Clin Pract Oncol. 2006 Feb; 3(2):60-1. PMID: 16462825.
    View in: PubMed
  281. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Guruangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol. 2006 Jan 01; 24(1):115-22. PMID: 16382120.
    View in: PubMed
  282. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Rich JN, Gururangan S, Gururangan I, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, Dowell JM, Badruddoja MA, McLendon RE, Lagattuta TF, Kicielinski KP, Dresemann G, Sampson JH, Friedman AH, Salvado AJ, Friedman HS. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005 Dec 20; 23(36):9359-68. PMID: 16361636.
    View in: PubMed
  283. Rich JN, Sathornsumetee S, Keir ST, Kieran MW, Laforme A, Kaipainen A, McLendon RE, Graner MW, Rasheed BK, Wang L, Reardon DA, Ryan AJ, Wheeler C, Dimery I, Bigner DD, Friedman HS. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res. 2005 Nov 15; 11(22):8145-57. PMID: 16299247.
    View in: PubMed
  284. McLendon RE, Herndon JE, West B, Reardon D, Wiltshire R, Rasheed BK, Quinn J, Friedman HS, Friedman AH, Bigner DD. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 2005 Oct 15; 104(8):1693-9. PMID: 16116609.
    View in: PubMed
  285. Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, Sathornsumetee S, Badruddoja M, McLendon R, Provenzale J, Herndon JE, Dowell JM, Burkart JL, Newton HB, Friedman AH, Friedman HS. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 2005 Oct 01; 104(7):1478-86. PMID: 16088964.
    View in: PubMed
  286. Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, Delaney SM, Vredenburgh J, Rich J, Friedman AH, Reardon DA, Sampson JH, Pegg AE, Moschel RC, Birch R, McLendon RE, Provenzale JM, Gururangan S, Dancey JE, Maxwell J, Tourt-Uhlig S, Herndon JE, Bigner DD, Friedman HS. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol. 2005 Oct 01; 23(28):7178-87. PMID: 16192602.
    View in: PubMed
  287. Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS. Chemotherapy and novel therapeutic approaches in malignant glioma. Front Biosci. 2005 Sep 01; 10:2645-68. PMID: 15970525.
    View in: PubMed
  288. Akabani G, Reardon DA, Coleman RE, Wong TZ, Metzler SD, Bowsher JE, Barboriak DP, Provenzale JM, Greer KL, DeLong D, Friedman HS, Friedman AH, Zhao XG, Pegram CN, McLendon RE, Bigner DD, Zalutsky MR. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med. 2005 Jun; 46(6):1042-51. PMID: 15937318.
    View in: PubMed
  289. Rich JN, Reardon DA, Quinn JA, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Gururangan S, Lyons P, Bigner DD, Friedman HS. A phase I trial of gefitinib (ZD1839) plus rapamycin for patients with recurrent malignant glioma. J Clin Oncol. 2005 Jun; 23(16_suppl):1565. PMID: 27946958.
    View in: PubMed
  290. Friedman HS, Quinn J, Rich J, Vredenburgh J, Desjardins A, Sathornsumetee S, Salvado A, Nikolova Z, Bigner D, Reardon D. Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results. J Clin Oncol. 2005 Jun; 23(16_suppl):1515. PMID: 27947123.
    View in: PubMed
  291. Reardon D, Cloughesy T, Conrad C, Prados M, Xia J, Mietlowski W, Dugan M, Mischel P, Friedman H, Yung A. A phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. J Clin Oncol. 2005 Jun; 23(16_suppl):3063. PMID: 27945588.
    View in: PubMed
  292. Vredenburgh JJ, Reardon D, Akabani G, Friedman A, Friedman H, McLendon R, Quinn J, Rich J, Zalutsky M, Bigner D. Results of a phase II study of 131 Iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):1510. PMID: 27947118.
    View in: PubMed
  293. Sathornsumetee S, Reardon DA, Quinn J, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Lyons P, Salvado A, Friedman HS. A phase I dose escalation study of imatinib mesylate plus standard-dosed temozolomide in the treatment of patients with malignant glioma. J Clin Oncol. 2005 Jun; 23(16_suppl):1540. PMID: 27947188.
    View in: PubMed
  294. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE, Dowell JM, Friedman AH, Friedman HS. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005 Jan 15; 103(2):329-38. PMID: 15558802.
    View in: PubMed
  295. Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ, Reese ED, Conrad CA, Traxler P, Lane HA, Reardon DA, Cavenee WK, Wang XF, Bigner DD, Friedman HS, Rich JN. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther. 2005 Jan; 4(1):101-12. PMID: 15657358.
    View in: PubMed
  296. Sampson JH, Reardon DA, Friedman AH, Friedman HS, Coleman RE, McLendon RE, Pastan I, Bigner DD. Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study. Neuro Oncol. 2005 Jan; 7(1):90-6. PMID: 15701286; PMCID: PMC1871629.
  297. Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD. Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther. 2004 Sep; 4(9):1453-71. PMID: 15335313.
    View in: PubMed
  298. Comin-Anduix B, Gualberto A, Glaspy J, Renteria R, Reardon D, Seja E, Economou JS, Littman B, Gomez-Navarro J, Ribas A. A methods study to define the performance specifications of MHC tetramer assays for immune monitoring of tumor immunotherapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9682. PMID: 28016258.
    View in: PubMed
  299. Reardon D, Friedman H, Yung WK, Brada M, Conrad C, Provenzale J, Jackson E, Serajuddin H, Chen B, Laurent D. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):1513. PMID: 28015364.
    View in: PubMed
  300. Badruddoja MA, Reardon DA, Akabani G, Friedman AH, Friedman HS, Rich JN, Quinn JA, Penne K, Vredenburgh JJ, Bigner DD. Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1569. PMID: 28015735.
    View in: PubMed
  301. Conrad C, Friedman H, Reardon D, Provenzale J, Jackson E, Serajuddin H, Laurent D, Chen B, Yung WK. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):1512. PMID: 28015365.
    View in: PubMed
  302. Desjardins A, Quinn JA, Reardon DA, Rich JN, Vredenburgh JJ, Efird C, Friedman HS. Phase II study of thalidomide and daily cyclophosphamide for adults with malignant glioma. J Clin Oncol. 2004 Jul 15; 22(14_suppl):1554. PMID: 28015449.
    View in: PubMed
  303. Badruddoja MA, Vredenburgh J, Peery TS, Reardon DA. Kluver-Bucy syndrome related to glioma. Neurology. 2004 Jul 13; 63(1):184. PMID: 15249638.
    View in: PubMed
  304. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Vredenburgh J, Gururangan S, Provenzale JM, Walker A, Schweitzer H, Bigner DD, Tourt-Uhlig S, Herndon JE, Affronti ML, Jackson S, Allen D, Ziegler K, Bohlin C, Lentz C, Friedman HS. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro Oncol. 2004 Apr; 6(2):145-53. PMID: 15134629; PMCID: PMC1871988.
  305. Reardon DA, Quinn JA, Rich JN, Gururangan S, Vredenburgh J, Sampson JH, Provenzale JM, Walker A, Badruddoja M, Tourt-Uhlig S, Herndon JE, Dowell JM, Affronti ML, Jackson S, Allen D, Ziegler K, Silverman S, Bohlin C, Friedman AH, Bigner DD, Friedman HS. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro Oncol. 2004 Apr; 6(2):134-44. PMID: 15134628; PMCID: PMC1871982.
  306. Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, Wikstrand CJ, Van Duyn LB, Dancey JE, McLendon RE, Kao JC, Stenzel TT, Ahmed Rasheed BK, Tourt-Uhlig SE, Herndon JE, Vredenburgh JJ, Sampson JH, Friedman AH, Bigner DD, Friedman HS. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004 Jan 01; 22(1):133-42. PMID: 14638850.
    View in: PubMed
  307. Sampson JH, Akabani G, Archer GE, Bigner DD, Berger MS, Friedman AH, Friedman HS, Herndon JE, Kunwar S, Marcus S, McLendon RE, Paolino A, Penne K, Provenzale J, Quinn J, Reardon DA, Rich J, Stenzel T, Tourt-Uhlig S, Wikstrand C, Wong T, Williams R, Yuan F, Zalutsky MR, Pastan I. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol. 2003 Oct; 65(1):27-35. PMID: 14649883.
    View in: PubMed
  308. Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, Vredenbergh J, Martin PL. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol. 2003 Jun 01; 21(11):2187-91. PMID: 12775745.
    View in: PubMed
  309. Reardon DA, Friedman HS, Powell JB, Gilbert M, Yung WK. Irinotecan: promising activity in the treatment of malignant glioma. Oncology (Williston Park). 2003 May; 17(5 Suppl 5):9-14. PMID: 12800600.
    View in: PubMed
  310. Korones DN, Benita-Weiss M, Coyle TE, Mechtler L, Bushunow P, Evans B, Reardon DA, Quinn JA, Friedman H. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer. 2003 Apr 15; 97(8):1963-8. PMID: 12673724.
    View in: PubMed
  311. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol. 2003 Feb 15; 21(4):646-51. PMID: 12586801.
    View in: PubMed
  312. Gururangan S, Cavazos CM, Ashley D, Herndon JE, Bruggers CS, Moghrabi A, Scarcella DL, Watral M, Tourt-Uhlig S, Reardon D, Friedman HS. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol. 2002 Jul 01; 20(13):2951-8. PMID: 12089224.
    View in: PubMed
  313. Quinn JA, Pluda J, Dolan ME, Delaney S, Kaplan R, Rich JN, Friedman AH, Reardon DA, Sampson JH, Colvin OM, Haglund MM, Pegg AE, Moschel RC, McLendon RE, Provenzale JM, Gururangan S, Tourt-Uhlig S, Herndon JE, Bigner DD, Friedman HS. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol. 2002 May 01; 20(9):2277-83. PMID: 11980998.
    View in: PubMed
  314. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002 Mar 01; 20(5):1389-97. PMID: 11870184.
    View in: PubMed
  315. Somlo G, Doroshow JH, Synold T, Longmate J, Reardon D, Chow W, Forman SJ, Leong LA, Margolin KA, Morgan RJ, Raschko JW, Shibata SI, Tetef ML, Yen Y, Kogut N, Schriber J, Alvarnas J. High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome. Br J Cancer. 2001 Jun 15; 84(12):1591-8. PMID: 11401310; PMCID: PMC2363687.
  316. Bowers G, Reardon D, Hewitt T, Dent P, Mikkelsen RB, Valerie K, Lammering G, Amir C, Schmidt-Ullrich RK. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene. 2001 Mar 15; 20(11):1388-97. PMID: 11313882.
    View in: PubMed
  317. Somlo G, Chow W, Hamasaki V, Leong L, Margolin K, Morgan R, Sniecinski I, Frankel P, Reardon D, Longmate E, Raschko J, Shibata S, O'Donnell M, Smith E, Tetef M, Forman S, Yen Y, Molina A, Doroshow H. Tandem-cycle high-dose melphalan and cisplatin with peripheral blood progenitor cell support in patients with breast cancer and other malignancies. Biol Blood Marrow Transplant. 2001; 7(5):284-93. PMID: 11400951.
    View in: PubMed
  318. Dong J, Gailani MR, Pomeroy SL, Reardon D, Bale AE. Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat. 2000 Jul; 16(1):89-90. PMID: 10874314.
    View in: PubMed
  319. Walter AW, Gajjar A, Reardon DA, Thompson SJ, Langston JW, Jones-Wallace D, Kun LE, Heideman RL. Tamoxifen and carboplatin for children with low-grade gliomas: a pilot study at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol. 2000 May-Jun; 22(3):247-51. PMID: 10864056.
    View in: PubMed
  320. Reardon DA, Jenkins JJ, Sublett JE, Burger PC, Kun LK. Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma. Pediatr Neurosurg. 2000 Apr; 32(4):187-91. PMID: 10940769.
    View in: PubMed
  321. Walter AW, Mulhern RK, Gajjar A, Heideman RL, Reardon D, Sanford RA, Xiong X, Kun LE. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol. 1999 Dec; 17(12):3720-8. PMID: 10577843.
    View in: PubMed
  322. Chow E, Jenkins JJ, Burger PC, Reardon DA, Langston JW, Sanford RA, Heideman RL, Kun LE, Merchant TE. Malignant evolution of choroid plexus papilloma. Pediatr Neurosurg. 1999 Sep; 31(3):127-30. PMID: 10708353.
    View in: PubMed
  323. Gajjar A, Fouladi M, Walter AW, Thompson SJ, Reardon DA, Merchant TE, Jenkins JJ, Liu A, Boyett JM, Kun LE, Heideman RL. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol. 1999 Jun; 17(6):1825-8. PMID: 10561221.
    View in: PubMed
  324. Chow E, Reardon DA, Shah AB, Jenkins JJ, Langston J, Heideman RL, Sanford RA, Kun LE, Merchant TE. Pediatric choroid plexus neoplasms. Int J Radiat Oncol Biol Phys. 1999 May 01; 44(2):249-54. PMID: 10760416.
    View in: PubMed
  325. Reardon DA, Entrekin RE, Sublett J, Ragsdale S, Li H, Boyett J, Kepner JL, Look AT. Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. Genes Chromosomes Cancer. 1999 Mar; 24(3):230-7. PMID: 10451703.
    View in: PubMed
  326. Merchant TE, Nguyen D, Thompson SJ, Reardon DA, Kun LE, Sanford RA. High-grade pediatric spinal cord tumors. Pediatr Neurosurg. 1999 Jan; 30(1):1-5. PMID: 10202299.
    View in: PubMed
  327. Reardon DA, Gajjar A, Sanford RA, Heideman RL, Walter AW, Thompson SJ, Merchant TE, Li H, Jenkins JJ, Langston J, Boyett JM, Kun LE. Bithalamic involvement predicts poor outcome among children with thalamic glial tumors. Pediatr Neurosurg. 1998 Jul; 29(1):29-35. PMID: 9867348.
    View in: PubMed
  328. Sublett JE, Entrekin RE, Look AT, Reardon DA. Chromosomal localization of the human smoothened gene (SMOH) to 7q32. 3 by fluorescence in situ hybridization and radiation hybrid mapping. Genomics. 1998 May 15; 50(1):112-4. PMID: 9628830.
    View in: PubMed
  329. Hutchinson RJ, Fryer CJ, Davis PC, Nachman J, Krailo MD, O'Brien RT, Collins RD, Whalen T, Reardon D, Trigg ME, Gilchrist GS. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol. 1998 Mar; 16(3):897-906. PMID: 9508171.
    View in: PubMed
  330. Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entrekin RE, Ragsdale ST, Valentine MB, Behm FG, Li H, Heideman RL, Kun LE, Shapiro DN, Look AT. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 1997 Sep 15; 57(18):4042-7. PMID: 9307291.
    View in: PubMed
  331. Reardon DA, Hanson CA, Roth MS, Castle VP. Lineage switch in Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 1994 Mar 01; 73(5):1526-32. PMID: 8111722.
    View in: PubMed
  332. Reardon D, Xie Y, Hung M. The microfocus assay system (mfas) - a simple quantitative assay to identify inhibitory drugs targeted against specific oncogenes. Oncol Rep. 1994 Jan; 1(1):37-41. PMID: 21607302.
    View in: PubMed
  333. Adams PT, Davenport RD, Reardon DA, Roth MS. Detection of circulating donor white blood cells in patients receiving multiple transfusions. Blood. 1992 Jul 15; 80(2):551-5. PMID: 1627807.
    View in: PubMed
  334. Franz W, Reardon D. Differential impact of abortion on adolescents and adults. Adolescence. 1992; 27(105):161-72. PMID: 1539493.
    View in: PubMed
  335. Reardon DA, Roskos R, Hanson CA, Castle V. Virus-associated hemophagocytic syndrome following bone marrow transplantation. Am J Pediatr Hematol Oncol. 1991; 13(3):305-9. PMID: 1665315.
    View in: PubMed
  336. Gladwin AM, Trowbridge EA, Slater DN, Reardon D, Martin JF. The size and number of bone marrow megakaryocytes in malignant lymphoma and their relationship to abnormalities in platelet count. Am J Hematol. 1990 Dec; 35(4):225-31. PMID: 2239916.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Reardon's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (634)
Explore
_
Co-Authors (107)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_